Am J Cardiol 1998; 81:594. Intravenous amiodarone is efficacious and hemodynamically well tolerated in the acute control of heart rote in critically ill patients who develop atrial tachyarrhythmias with rapid ventricular response refractory to conventional treatment.
Pretreatment with amiodarone before intensive care administration, paroxysmal versus persistent AT, catecholamine infusion, and fluid and magnesium loading were among the covariates assessed in the model. We retrospectively studied intensive care unit patients (n = 38) who received intravenous amiodarone for heart rate control in the setting of hemodynamically destabilizing atrial tachyarrhythmias resistant to conventional heart rate control measures. In patients with structural heart disease such as CAD, amiodarone can be used to restore and maintain sinus rhythm. 2001 Jun;29(6):1149-53. doi: 10.1097/00003246-200106000-00011.Tomcsányi J, Arabadzisz H, Zsoldos A, Marosi A, Beck K.Moran JL, Gallagher J, Peake SL, Cunningham DN, Salagaras M, Leppard P.Crit Care Med. Aims Amiodarone is the gold-standard medication to control heart rate in critically ill patients with atrial tachyarrhythmias (ATs); however, effective doses and covariates influencing its efficacy remain unknown. COVID-19 is an emerging, rapidly evolving situation. Atrial fibrillation was present in 33 patients and atrial flutter in 5 patients. Elsevier Science
2018 Dec;48(12):1033-1080. doi: 10.4070/kcj.2018.0339.Chest.
2019 Jan;49(1):22-45. doi: 10.4070/kcj.2018.0349.Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, Kang KW, Shim J, Lim HE, Park J, Lee SR, Lee YS, Kim JB; KHRS Atrial Fibrillation Guideline Working Group.Korean Circ J. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug … Atrial fibrillation (AF) is the most common type of arrhythmia and the leading cause of cardioembolic stroke, with AF patients being five times more likely to experience a stroke than those without AF.1 The median age for patients with AF is … Beneficial changes were also noted in pulmonary artery occlusive pressure and cardiac output. Both rate and rhythm control are options for treatment of atrial fibrillation (AF). 8 No. Unable to load your collection due to an error Due to of the risk of toxicity and long-term side effects, amiodarone is used for chronic rate control … You may continue to have side effects from this medicine after you stop using it. Amiodarone is considered a "broad spectrum" antiarrhythmic … Please enable it to take advantage of the complete set of features! Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, Siostrzonek P, Heinz G.Crit Care Med. Although amiodarone has many side effects, some of which are severe and potentially fatal, it has been successful in treating many arrhythmias when other antiarrhythmic drugs have failed.
Amiodarone may be an alternative agent for heart rate control if conventional measures are ineffective. Amiodarone is an oral and injectable drug that is used to correct abnormal rhythms of the heart. Amiodarone: Oral amiodarone has significant rate-controlling properties in addition to its antiarrhythmic actions and may be useful in refractory patients for ventricular rate control during AF.
Kamiya K, … Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Unable to load your delegates due to an error doi: 10.1016/s0002-9149(97)00962-4. Oral amiodarone is unlikely to cause hypotension when administered at recommended doses. Elsevier Science Pacing Clin Electrophysiol 2004; 27:901. Class effect. This site needs JavaScript to work properly. … You have reached the maximum number of saved studies (100).Please remove one or more studies before adding more.Joe Elie Salem, Groupe Hospitalier Pitie-SalpetriereAims Amiodarone is the gold-standard medication to control heart rate in critically ill patients with atrial tachyarrhythmias (ATs); however, effective doses and covariates influencing its efficacy remain unknown.